ABSTRACT
Objective To derive a predicted probability of death (PDeathLabs) based upon complete value sets for 11 clinical measurements (CM) obtained on patients prior to their diagnosis of COVID-19. PDeathLabs is intended for use as a summary metric for baseline metabolic status in multivariate models for COVID-19 death.
Methods Cases were identified through the COVID-19 Shared Data Resource (CSDR) of the Department of Veterans Affairs. The diagnosis required at least one positive nucleic acid amplification test (NAAT). The primary outcome was death within 60 days of the first positive test. We retrieved all values for systolic blood pressure (SBP), diastolic blood pressure (DBP), O2 saturation (O2SAT), body mass index (BMI), estimated glomerular filtration rate (EGFR), alanine aminotransferase (ALT), serum albumin (ALB), hematocrit (HCT), LDL cholesterol (LDL) hemoglobin A1c (A1C), and HDL cholesterol (HDL) if they were done at least 14 days prior to the NAAT. Clinicians evaluate several attributes of CM that are of critical importance: metabolic control, disease burden, chronicity, refractoriness, tendency to relapse, temporal trends, and lability. We derived 1-3 parameters for each of these attributes: the most recent value (metabolic control); time-weighted average and abnormal area under a severity versus time curve (disease burden); time and number of readings above or below goal (chronicity); longest abnormal cluster and time/number of consecutive readings above goal if the last value was abnormal (refractoriness); number of abnormal clusters (tendency to relapse); long- and short-term changes (temporal trends); and coefficient of variation and mean deviation between consecutive readings (lability). We created computer programs to derive cumulative values for these 13 parameters for all 11 CM as each new value is added. A fitted logistic model was developed for each CM to determine which of the 13 parameters contributed to the risk of death. A main logistic model was developed to determine which of the 13 * 11 = 143 metabolic parameters were independently predictive of death. The resulting model was used to derive PDeathLabs for each patient and the area under its receiver operating characteristic (ROC) curve calculated. Single variable logistic models were also derived for age at diagnosis, the Charlson 2-year (Charl2Yr) and lifetime (CharlEver) scores, and the Elixhauser 2-year (Elix2Yrs) and lifetime (ElixEver) scores. Stata was used to compare the ROCs for PDeathDx and each of the other metrics.
Results On September 30, 2021 there were 347,220 COVID-19 patients in the CSDR. 329,491 (94.9%) patients had CM performed at least 14 days prior to the COVID-19 diagnosis and form the basis for this report. 17,934 (5.44%) died within 60 days of the diagnosis. On the subset regressions, the number of significant parameters ranged from all 13 for SBP to 7 for HDL. 239,393 patients had complete sets of data for developing the main model. Of 143 candidate predictors, 49 parameters were identified as statistically significant, independent predictors of death. The most influential domains were the most recent value, disease burden, temporal trends, and tendency to relapse. The ROC area for PDeathLabs was 0.785 +/- 0.002. No difference was found in the ROC areas of PDeathLabs and age at diagnosis (0.783 +/- 0.002; P = NS). However, the ROC area for PDeathLabs was significantly greater than that of Charl2Yrs (0.704 +/- 0.002; P < 0.001), CharlEver (0.729 +/- 0.002; P < 0.001), Elix2Yrs (0.675 ± 0.002; P < 0.001), and ElixEver (0.707 +/- 0.002; P < 0.001). A poor prognosis was found for chronic systolic hypertension. On the other hand, a higher BMI was protective once SBP, DBP, HDL, LDL and A1C were considered.
Conclusions Our study confirms that parameters derived for 11 CM are significant determinants of COVID-19 death. The most recent value should not be selected over other parameters for multivariate modeling unless there is a physiologic basis for doing so. PDeathLabs has the same discriminating power as age at diagnosis and outperforms comorbidity indices as a summary metric for pre-existing conditions. If validated by others, this approach provides a robust approach to handling CM in multivariate models.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the New Mexico VA Health Care System gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
